Dr. Grivas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
University of Washington / SCCA
825 Eastlake Ave E, MS: G4-830
Seattle, WA 98109Phone+1 206-606-7595- Is this information wrong?
Summary
- I am a medical oncologist by training with expertise in genitourinary cancers, such as bladder cancer, prostate cancer and testis cancer. I am dedicated to efficient, personalized and outstanding patient care. I've also had a main role in clinical trials that led to the FDA approval of new drugs for bladder/urothelial cancer. In addition, I've spent time giving lectures in several countries, educating oncologists, other healthcare providers and trainees, leading innovative clinical trials, reviewing grant proposals and manuscripts, and publishing novel and important research.
Education & Training
- University of MichiganGME Scholars Health Care Administration and Leadership Program, 2012 - 2014
- University of Michigan Health SystemFellowship, Hematology and Medical Oncology, 2010 - 2013
- Drexel University College of Medicine/Hahnemann University HospitalResidency, Internal Medicine, 2007 - 2010
- University of Patras School of MedicinePh.D., Medical Oncology, 2005 - 2009
- University of Patras School of MedicineClass of 2005, M.D.
Certifications & Licensure
- WA State Medical License 2017 - 2024
- OH State Medical License 2014 - 2019
- MI State Medical License 2010 - 2017
- PA State Medical License 2007 - 2010
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Award for Contributions in Cancer Care and Research Athens, Greece, 2018
- GU Malignancies Pilot Award Case Comprehensive Cancer Center, 2017
- International Bladder Cancer Network Award IBCN, 2016
- Join now to see all
Clinical Trials
- Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Start of enrollment: 2019 Mar 22
- Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma Start of enrollment: 2019 Jan 17
Publications & Presentations
PubMed
- Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial.Sumanta K Pal, Petros Grivas, Shilpa Gupta, Nazli Dizman, Zeynep Zengin, Begona P Valderrama, Alejo Rodriguez-Vida, Florian Roghmann, Elena Sevillano Fernandez, Surena...> ;European Urology. 2024 Apr 4
- Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.Jacob B Leary, Thomas Enright, Dimitra Rafailia Bakaloudi, Alina Basnet, Gennady Bratslavsky, Joseph Jacob, Philippe E Spiess, Roger Li, Andrea Necchi, Ashish M Kamat,...> ;Targeted Oncology. 2024 Apr 3
- Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.Roisin M Connolly, Victoria Wang, David M Hyman, Petros Grivas, Edith P Mitchell, John J Wright, Elad Sharon, Robert J Gray, Lisa M McShane, Larry V Rubinstein, David ...> ;Clinical Cancer Research. 2024 Apr 1
- Join now to see all
Journal Articles
- Association of Clonal Hematopoiesis in DNA Repair Genes with Prostate Cancer Plasma Cell-Free DNA Testing InterferenceMichael T Schweizer, Petros Grivas, Heather H Cheng, Evan Y Yu, JAMA Oncology
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial CarcinomaCora N Sternberg, Jeanny B Aragon-Ching, Daniel P Petrylak, Petros Grivas, The New England Journal of Medicine
- HER-3 in Colorectal Tumourigenesis: From mRNA Levels Through Protein Status to Clinicopathologic RelationshipsPetros Grivas, MD, European Journal of Cancer
- Join now to see all
Lectures
- PrE0807 phase Ib feasibility trial of neoadjuvant nivolumab (N)/lirilumab (L) in cisplatin-ineligible muscle-invasive bladder cancer (BC).2019 ASCO Annual Meeting - 6/1/2019
- Novel Therapeutic Strategies for Advanced Bladder and Penile Cancer2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Association of circulating tumor (ct)-DNA genomic alterations (GA) with outcomes in metastatic urothelial carcinoma (mUC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Join now to see all
Authored Content
- HER-3 in Colorectal Tumourigenesis: From mRNA Levels Through Protein Status to Clinicopathologic RelationshipsDecember 2018
- Recommendations for Follow-up of Muscle-Invasive Bladder Cancer Patients: A Consensus by the International Bladder Cancer NetworkFebruary 2018
Press Mentions
- Tip Sheet: The Role of Necrotic Tumor Cores in Metastatic Spread, Why Rural Health Policy Matters — and a Lifetime Achievement AwardMarch 2nd, 2023
- A Novel Imaging Modality, FAP Imaging for Sufferers with Bladder Most CancersOctober 18th, 2022
- Healio Announces First Disruptive Innovators in Hem/OncJune 4th, 2022
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Other Languages
- Greek, Italian
Hospital Affiliations
- Fred Hutchinson Cancer CenterSeattle, Washington
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: